Please login to the form below

Not currently logged in
Email:
Password:

Kala names Howard Rosen as chairman

He is former CEO of Pearl Therapeutics and VP at Gilead
Howard Rosen, Kala

Kala Pharmaceuticals has appointed life sciences industry veteran Howard Rosen as chairman of the board of directors.

Rosen has held several senior roles at major biotechs, including his current positions on the board of directors at AcelRX, Aldea, Entrega and PaxVax, where he is also chairman.

His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to $1.15bn, as well as a period as VP, commercial strategy at Gilead Sciences and president of Johnson & Johnson subsidiary ALZA Corporation.

Kala's president and CEO Guillaume Pfefer commented on this rich experience when welcoming Rosen.

“Howard's extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Pfefer, who joined the eyecare specialist from Sanofi in 2012.

8th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...